B-vit in the joint

Assessing penetration of high dose Nicotinamide (Vitamin B3) in synovial fluid

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20367

Enrollment

Registered

2018-06-05

Start date

2018-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile idopathic arthritis, JIA, juvenile rheumatoid arthritis

Interventions

Additional NAM therapy with 1,8g/m2/day in 3 doses for the duration of 3 days before intra-articular corticosteroid injection.

Eligibility

Inclusion criteria

Inclusion criteria: - Patients with a diagnosis of oligo-articular or poly-articular JIA with active disease in 1 or multiple joints and an indication for intra-articular corticosteroid injection. - Age of 16 years or older and under treatment of the pediatric rheumatology department of the WKZ/UMC Utrecht.

Exclusion criteria

Exclusion criteria: - No informed consent possible by patient - Inability to take oral medication - Participation in other interventional trials

Design outcomes

Primary

Measure	Time frame
In this phase II trial essential preliminary information will be gained on the peak NAM levels in the synovial fluid.	—

Contacts

Public ContactBast Vastert

0887554339

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)